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Background: Myelin-oligodendrocyte glycoprotein antibody (MOG antibodies) was found in various demyelinated
diseases. This is the first report of a patient with longitudinally extensive transverse myelitis with an extremely high
titer of MOG antibodies after an influenza infection. This case supports the view that MOG antibodies are linked to
longitudinally extensive transverse myelitis and that influenza infection might trigger the MOG antibodies.
Case presentation: A 32-year-old healthy male developed high fever, dysesthesia and paraesthesia below the C2
area, muscle weakness of the bilateral lower extremities, and urinary retention ten days after an influenza type A
infection. Magnetic resonance imaging revealed a longitudinal lesion in the spinal cord extending from C2 to the
spinal conus. There were no lesions in the brain or optic nerves. Established cell-based immunoassays revealed that
he was positive for MOG antibodies (titer = 65,536) and negative for anti-aquaporin 4 antibodies (AQP4 antibodies).
He fully recovered after steroid pulse therapy followed by 60 mg prednisolone.
Conclusion: This is the first report of influenza A-associated longitudinally extensive transverse myelitis with a high
titer anti-MOG antibodies. Our case report supports a relationship between anti-MOG antibodies and longitudinally
extensive transverse myelitis, which was triggered by influenza infection. Further studies are needed to establish the
clinical significance of anti-MOG antibodies for diagnosis, treatment, and prognosis.
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Myelin oligodendrocyte glycoprotein (MOG) localizes
on the outermost surface of the myelin sheath and oligo-
dendrocytes in the central nervous system (CNS). Auto-
antibodies against MOG are reportedly found in patients
with a spectrum of inflammatory demyelinating diseases
of the CNS, including acute disseminated encephalomye-
litis, multiple sclerosis, transverse myelitis, and neuromye-
litis optica (NMO) [1]. NMO is a severe inflammatory
disorder of the central nervous system that predominantly
affects the optic nerves and spinal cord. Most patients
with NMO have antibodies against the water channel* Correspondence: nobu-m@juntendo.ac.jp
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unless otherwise stated.aquaporin-4 (AQP4 antibodies), which are thought to be
pathogenic [2-4]. However, some patients are seronegative
for AQP4 antibody; the lack of a biomarker makes diagno-
sis and management of these patients difficult. Many clini-
cians perceive these patients to be similar to those with
AQP4-Abs and manage them in the same way. Recently,
some groups showed that some AQP4 antibody seronega-
tive patients have antibodies against MOG [5-7]. They also
demonstrated differences in clinical phenotypes and re-
sponsiveness of therapy between the AQP4 antibody sero-
negative and MOG antibody seropositive patients with
NMO/NMO spectrum disorder (NMOSD). Detection of
MOG antibodies is important for patients management.
Mice that are transgenic for MOG-specific T-cell and
B-cell receptors develop spontaneous experimental auto-
immune encephalomyelitis (EAE) [8-11]. Recent studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 T2-imaging MRI of cervical (C)/thoracic (Th) spinal
cord on admission (A) and after treatment (B). On admission
(day 10), there was a longitudinal T2 high intensity area, extending
from C2 to the conus (arrowheads), but the lesion resolved
completely after treatment (day 20).
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syndrome closely resembling NMO. Although the clinical
spectrum of MOG IgG associated diseases in humans is
reflected in different experimental models, the role of
MOG antibodies in pathogenesis is still unclear. Here we
describe a patient who suffered from longitudinal ex-
tended TM (LETM) with high-titer MOG antibodies
following an influenza-A infection and his AQP4 anti-
body was negative.
Case presentation
A 32-year-old male, without any relevant medical his-
tory, felt general fatigue and had a high fever of 38.9 de-
grees Celsius. The following day, he was diagnosed with
influenza type A by nasal swab test at a clinic, and pre-
scribed oseltamivir. His symptoms were ameliorated suf-
ficiently that he was able to return to work from day 5
and go winter climbing on days 6–7. On day 9, however,
he experienced whole body pain, urinary retention, and
weakness of the bilateral lower extremities; these symp-
toms then became exacerbated. Eventually, he was un-
able to walk by himself, and came to our hospital on day
10. His body temperature was 39.4 degrees Celsius and
there was marked bilateral lower extremity weakness.
Deep tendon reflexes were normal in both the upper
and lower limbs. He had paraesthesia and dysesthesia in
the entire area below level C2. Both superficial and deep
sensory systems were disturbed in the same area, espe-
cially in the lateral sides of the femur (50% decrease)
and crus (40% decrease). Meningial signs, such as neck
stiffness and Kernig’s sign, were positive. He had no vis-
ual field deficits.
His laboratory data showed a white blood cell count of
13800/μl (Neutrophil 83%) and a c-reactive protein level
of 0.4 mg/dl. An anti-nuclear antibody test revealed a
titer of 1:320 with a nucleolar pattern, but collagen dis-
eases associated with nucleolar antibodies, such as sys-
temic lupus erythematosus and scleroderma, were
negative according to additional tests of other anti-
bodies. The cerebrospinal fluid exhibited a cell count of
247 cells/μl (monocyte 77.1%, lymphocyte 54.5%), an el-
evated protein level (92 mg/dl), and a myelin basic pro-
tein concentration over 2000 pg/ml (IL-6 9490 pg/ml),
suggesting strong inflammation of the central nervous
system. The oligoclonal band was negative. Established
cell-based immunoassays revealed that he was positive
for anti-MOG antibodies and negative for anti-AQP4
antibodies. His MOG antibody titer was as high as
65,536, which was extremely high compared to past re-
port in the patients with demyelinated diseases included
with NMOSD, which median (range) MOG antibody ti-
ters was 4,096 (128–32,768) in single attack patients
[12]. T2 imaging MRI showed a long hyperintense lesion
in the spinal cord extending from C2 to the medullaryconus, mainly lying in thoracic spinal cord. The lesion
occupied grey matter, making “H” shape, partly spread-
ing to white matter. The lesion was not enhanced by
gadolinium-DTPA (Figure 1). Nerve conduction vel-
ocity was normal. We diagnosed him with anti-MOG
antibody-positive longitudinally extensive transverse
myelitis, and started immunosuppression therapy with
intravenous methylprednisolone (1000 mg/day) for
three consecutive days, followed by oral prednisolone
(60 mg per day). The patient was able to use a wheel-
chair without any help on day 5 after admission, and he
recovered the full strength of his lower extremities by
day 6. Paraesthesia and sensory loss gradually improved
and resolved by day 10; dysesthesia in the bilateral lower
limbs and thermoanesthesia below the Th4 level also
improved, and resolved completely one month later.
After two weeks of 60 mg per day prednisolone, we
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6 weeks. After one week of therapy, the MOG antibody
titer declined to 16,384, one fourth of the first labora-
tory data. After one month, the MOG antibody titer de-
creased to 4,096.
Discussion
Here, we describe the first reported case of a patient
with LETM following an influenza type A infection who
was also positive for anti-MOG autoantibodies. Recently,
it was reported that autoantibodies against MOG are
found in patients with a spectrum of inflammatory de-
myelinating diseases of the CNS. Among AQP4 antibody
seronegative NMO patients, 21.1% were reported to
have high titers of MOG antibodies [6]. MOG antibody
positive NMO has specific clinical and epidemiological
features different from AQP4 positive NMO [6]. The
sexual ratio is 44:56, while 90% of AQP4-positive NMO
patients are female. The average age of onset in MOG-
positive NMO is 32.29 ± 17.1 years, obviously younger
than the 44.86 ± 14.8 years reported for AQP4 antibody
positive NMO patients. MOG antibody positive patients
had better outcomes from the episode, with better re-
covery, expanded disability status scale (EDSS) scores,
and a low risk for visual and motor disability [6]. On
MRI, a thoracic spinal lesion involving the conus and
brain lesions adjacent to the fourth ventricle are seen
more frequently in MOG antibody positive NMO than
in AQP4 antibody positive NMO. High anti-MOG anti-
body titers are frequently observed among pediatric pa-
tients with recurrent optic neuritis [13]. Huppke et al.
reported that seven pediatric patients with acute dissem-
inated encephalomyelitis (ADEM) followed by optic
neuritis were positive for anti-MOG antibodies, but not
anti-AOP4 antibodies [14].
Influenza infection triggers various autoimmune dis-
eases, included neurological disorders (e.g., Guillain-Barre
syndrome and ADEM) [15-17]. However, not only influ-
enza infection, influenza vaccination could be a possible
cause of CNS demyelinating diseases [18]. Among 71
cases of post-vaccination CNS demyelinating diseases,
influenza vaccination was related to 21 cases, occupying
the biggest ratio. Majority of demyelination (especially
following influenza vaccination) occur in optic nerves
and myelon. This predisposition to the spinal cord and
the optic nerves is reminiscent to NMO/NMOSD. In
general, the symptoms of post-vaccination demyelinating
diseases appear 14.2 days (mean) after immunization [18].
Here, we present the first report of a patient with anti-
MOG antibody-positive LETM after influenza infection.
Previously, Nakamura et al. reported a patient with NMO
who showed optic neuritis and longitudinally extensive le-
sions in the thoracic cord without anti-AQP4 antibodies.
They did not examine the titer of anti-MOG antibodies[19]. The mechanisms of development and function of
anti-MOG antibodies remain unclear. Our case showed
that influenza infection may trigger anti-MOG-IgG posi-
tive myelitis; following treatment, the titer of anti-MOG
antibody decreased together with clinical symptoms. Add-
itional studies are needed to establish the clinical signifi-
cance of anti-MOG antibodies for diagnosis, treatment,
and prognosis.
Conclusion
We have presented the first report of a patient with
MOG-positive LETM at the C2 to conus level without
optic neuritis after influenza A infection.
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